SEARCH

SEARCH BY CITATION

References

  • 1
    Eriksson BI, Quinlan DJ. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs 2006; 66: 141129.
  • 2
    Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96: 27484.
  • 3
    Anderson FA Jr., Hirsh J, White K, Fitzgerald RH Jr. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996–2001: findings from the Hip and Knee Registry. Chest 2003; 124: 349S56S.
  • 4
    Tapson VF, Hyers TM, Waldo AL, Ballard DJ, Becker RC, Caprini JA, Khetan R, Wittkowsky AK, Colgan KJ, Shillington AC. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med 2005; 165: 145864.
  • 5
    Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S33S.
  • 6
    Stassen JM, Hauel NH, Nar H, Ries UJ, Priepke HWM. Identification and in vitro characterization of BIBR 953 ZW, a novel synthetic low molecular weight direct thrombin inhibitor. Thromb Haemost 2001; 86(Suppl.): P755[abstract].
  • 7
    Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45: 175766.
  • 8
    Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 55563.
  • 9
    Liesenfeld KH, Schafer HG, Troconiz IF, Tillmann C, Eriksson BI, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006; 62: 52737.
  • 10
    Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 10311.
  • 11
    Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 13444.
  • 12
    Kalebo P, Ekman S, Lindbratt S, Eriksson BI, Pauli U, Zachrisson BE, Close P. Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment. Thromb Haemost 1996; 76: 8936.
  • 13
    Kalebo P, Anthmyr BA, Eriksson BI, Zachrisson BE. Optimization of ascending phlebography of the leg for screening of deep vein thrombosis in thromboprophylactic trials. Acta Radiol 1997; 38: 3206.
  • 14
    Committee for Proprietary Medicinal Products. Points to Consider on Clinical Investigation of Medicinal Products for Prophylaxis of Intra- and Post-Operative Venous Thromboembolic Risk. London: The European Agency for the Evaluation of Medicinal Products, 2000. Guideline no. CPMP/EWP/707/98.
  • 15
    Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, Wheeler HB. Prevention of venous thromboembolism. Chest 2001; 119: 132S75S.
  • 16
    Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003; 89: 28896.
  • 17
    Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kalebo P, Panfilov S, Eskilson C, Andersson M. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 24906.
  • 18
    Leclerc JR, Geerts WH, Desjardins L, Jobin F, Laroche F, Delorme F, Haviernick S, Atkinson S, Bourgouin J. Prevention of deep vein thrombosis after major knee surgery – a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992; 67: 41723.
  • 19
    Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63: 65560.
  • 20
    Committee for Proprietary Medicinal Products. Points to Consider on Switching Between Superiority and Non-Inferiority. London: The European Agency for the Evaluation of Medicinal Products, 2000. Available at: http://www.emea.eu.int/pdfs/human/ewp/048299en.pdf. (accessed July 25, 2007).
  • 21
    Lotke PA, Lonner JH. Deep venous thrombosis prophylaxis: better living through chemistry – in opposition. J Arthroplasty 2005; 20: 157.
  • 22
    FDA Working Group. CDER-PhRMA-AASLD Conference 2000: clinical white paper on drug-induced hepatotoxicity. Rockville: Food and Drug Administration, November 2000. http://www.fda.gov/cder/livertox/clinical.pdf. (accessed January 15, 2007).
  • 23
    Eriksson BI, Dahl OE, Rosencher N, Kurth AA, Van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 94956.
  • 24
    Friedman RJ, Caprini JA, Comp PC, Davidson BL, Francis CW, Ginsberg J, Huo M, Lieberman J, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee J. Dabigatran etexilate versus enoxaparin in preventing venous thromboembolism following total knee arthroplasty [abstract]. J Thromb Haemost 2007; 5(Suppl. 2): OC051.